These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32247206)

  • 1. Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer.
    Draulans C; van der Heide UA; Haustermans K; Pos FJ; van der Voort van Zyp J; De Boer H; Groen VH; Monninkhof EM; Smeenk RJ; Kunze-Busch M; De Roover R; Depuydt T; Isebaert S; Kerkmeijer LGW
    Radiother Oncol; 2020 Jun; 147():92-98. PubMed ID: 32247206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
    Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
    Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: Toxicity in the FLAME randomized controlled trial.
    Monninkhof EM; van Loon JWL; van Vulpen M; Kerkmeijer LGW; Pos FJ; Haustermans K; van den Bergh L; Isebaert S; McColl GM; Smeenk RJ; Noteboom J; Walraven I; Peeters PHM; van der Heide UA
    Radiother Oncol; 2018 Apr; 127(1):74-80. PubMed ID: 29336835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study.
    Jorgo K; Polgar C; Major T; Stelczer G; Herein A; Pocza T; Gesztesi L; Agoston P
    Pathol Oncol Res; 2020 Apr; 26(2):905-912. PubMed ID: 30888646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
    Ma TM; Lamb JM; Casado M; Wang X; Basehart TV; Yang Y; Low D; Sheng K; Agazaryan N; Nickols NG; Cao M; Steinberg ML; Kishan AU
    BMC Cancer; 2021 May; 21(1):538. PubMed ID: 33975579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.
    Herrera FG; Valerio M; Berthold D; Tawadros T; Meuwly JY; Vallet V; Baumgartner P; Thierry AC; De Bari B; Jichlinski P; Kandalaft L; Coukos G; Harari A; Bourhis J
    Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):320-334. PubMed ID: 30267761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute side effects after definitive stereotactic body radiation therapy (SBRT) for patients with clinically localized or locally advanced prostate cancer: a single institution prospective study.
    Jorgo K; Polgar C; Stelczer G; Major T; Gesztesi L; Agoston P
    Radiol Oncol; 2021 Jul; 55(4):474-481. PubMed ID: 34253001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results.
    Bruynzeel AME; Tetar SU; Oei SS; Senan S; Haasbeek CJA; Spoelstra FOB; Piet AHM; Meijnen P; Bakker van der Jagt MAB; Fraikin T; Slotman BJ; van Moorselaar RJA; Lagerwaard FJ
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1086-1094. PubMed ID: 31419510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients.
    Nicosia L; Mazzola R; Rigo M; Figlia V; Giaj-Levra N; Napoli G; Ricchetti F; Corradini S; Ruggieri R; Alongi F
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2547-2554. PubMed ID: 31324979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
    Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
    Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial.
    Kerkmeijer LGW; Groen VH; Pos FJ; Haustermans K; Monninkhof EM; Smeenk RJ; Kunze-Busch M; de Boer JCJ; van der Voort van Zijp J; van Vulpen M; Draulans C; van den Bergh L; Isebaert S; van der Heide UA
    J Clin Oncol; 2021 Mar; 39(7):787-796. PubMed ID: 33471548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results.
    Aluwini S; van Rooij P; Hoogeman M; Kirkels W; Kolkman-Deurloo IK; Bangma C
    Radiat Oncol; 2013 Apr; 8():84. PubMed ID: 23570391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
    Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
    Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity, quality of life, and PSA control after 50 Gy stereotactic body radiation therapy to the dominant intraprostatic nodule with the use of a rectal spacer: results of a phase I/II study.
    Cloitre M; Valerio M; Mampuya A; Rakauskas A; Berthold D; Tawadros T; Meuwly JY; Heym L; Duclos F; Vallet V; Zeverino M; Jichlinski P; Prior J; Roth B; Bourhis J; Herrera FG
    Br J Radiol; 2023 Apr; 96(1145):20220803. PubMed ID: 36745031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study.
    Di Muzio NG; Fodor A; Noris Chiorda B; Broggi S; Mangili P; Valdagni R; Dell'Oca I; Pasetti M; Deantoni CL; Chiara A; Berardi G; Briganti A; Calandrino R; Cozzarini C; Fiorino C
    Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):490-500. PubMed ID: 26961088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SABR for High-Risk Prostate Cancer: A Prospective Multilevel MRI-Based Dose Escalation Trial.
    Hannan R; Salamekh S; Desai NB; Garant A; Folkert MR; Costa DN; Mannala S; Ahn C; Mohamad O; Laine A; Kim DWN; Dickinson T; Raj GV; Shah RB; Wang J; Jia X; Choy H; Roehrborn CG; Lotan Y; Timmerman RD
    Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):290-301. PubMed ID: 34774676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic body radiation therapy with optional focal lesion ablative microboost in prostate cancer: Topical review and multicenter consensus.
    Draulans C; De Roover R; van der Heide UA; Haustermans K; Pos F; Smeenk RJ; De Boer H; Depuydt T; Kunze-Busch M; Isebaert S; Kerkmeijer L
    Radiother Oncol; 2019 Nov; 140():131-142. PubMed ID: 31276989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic MRI-guided radiation therapy for localized prostate cancer (SMILE): a prospective, multicentric phase-II-trial.
    Ristau J; Hörner-Rieber J; Buchele C; Klüter S; Jäkel C; Baumann L; Andratschke N; Garcia Schüler H; Guckenberger M; Li M; Niyazi M; Belka C; Herfarth K; Debus J; Koerber SA
    Radiat Oncol; 2022 Apr; 17(1):75. PubMed ID: 35428327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standard and Hypofractionated Dose Escalation to Intraprostatic Tumor Nodules in Localized Prostate Cancer: 5-Year Efficacy and Toxicity in the DELINEATE Trial.
    Tree AC; Satchwell L; Alexander E; Blasiak-Wal I; deSouza NM; Gao A; Greenlay E; McNair H; Parker C; Talbot J; Dearnaley D; Murray J
    Int J Radiat Oncol Biol Phys; 2023 Feb; 115(2):305-316. PubMed ID: 36150450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The early result of whole pelvic radiotherapy and stereotactic body radiotherapy boost for high-risk localized prostate cancer.
    Lin YW; Lin LC; Lin KL
    Front Oncol; 2014; 4():278. PubMed ID: 25401085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.